Patents by Inventor George L. Kenyon
George L. Kenyon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6979566Abstract: A water soluble derivative of buckministerfullerene (C50) having antiviral and virucidal properties is used to inhibit human retroviral replication and infections. The derivatized fullerene is symmetrically substituted with polar organic moieties containing 1 to 20 carbon atoms and optionally further containing oxygen or nitrogen.Type: GrantFiled: February 1, 2003Date of Patent: December 27, 2005Assignee: The Regents of the University of CaliforniaInventors: Simon H. Friedman, Raymond F. Schinazi, Fred Wudl, Craig L. Hill, Diane L. DeCamp, Rintje P. Sijbesma, George L. Kenyon
-
Publication number: 20040044062Abstract: A water soluble derivative of buckministerfullerene (C50) having antiviral and virucidal properties is used to inhibit human retroviral replication and infections. The derivatized fullerene is symmetrically substituted with polar organic moieties containing 1 to 20 carbon atoms and optionally further containing oxygen or nitrogen.Type: ApplicationFiled: February 1, 2003Publication date: March 4, 2004Inventors: Simon H. Friedman, Raymond F. Schinazi, Fred Wudl, Craig L. Hill, Diane L. DeCamp, Rintje P. Sijbesma, George L. Kenyon
-
Patent number: 6613771Abstract: A water soluble derivative of buckministerfullerene (C60) having antiviral and virucidal properties is used to inhibit human retroviral replication and infections. The derivatized fullerene is symmetrically substituted with polar organic moieties containing 1 to 20 carbon atoms and optionally further containing oxygen or nitrogen.Type: GrantFiled: January 25, 2001Date of Patent: September 2, 2003Assignee: The Regents of the University of CaliforniaInventors: Simon H. Friedman, Raymond F. Schinazi, Fred Wudl, Craig L. Hill, Diane L. DeCamp, Rintje P. Sijbesma, George L. Kenyon
-
Publication number: 20010041801Abstract: A water soluble derivative of buckministerfullerene (C60) having antiviral and virucidal properties is used to inhibit human retroviral replication and infections. The derivatized fullerene is symmetrically substituted with polar organic moieties containing 1 to 20 carbon atoms and optionally further containing oxygen or nitrogen.Type: ApplicationFiled: January 25, 2001Publication date: November 15, 2001Applicant: The Regents of the University of CaliforniaInventors: Simon H. Friedman, Raymond F. Schinazi, Fred Wudl, Craig L. Hill, Diane L. DeCamp, Rintje P. Sijbesma, George L. Kenyon
-
Patent number: 6204391Abstract: A water soluble derivative of buckministerfullerene (C60) having antiviral and virucidal properties is used to inhibit human retroviral replication and infections. The derivatized fullerene is symmetrically substituted with polar organic moieties containing 1 to 20 carbon atoms and optionally further containing oxygen or nitrogen.Type: GrantFiled: September 21, 1998Date of Patent: March 20, 2001Assignee: The Regents of the University of CaliforniaInventors: Simon H. Friedman, Raymond F. Schinazi, Fred Wudl, Craig L. Hill, Diane L. DeCamp, Rintje P. Sijbesma, George L. Kenyon
-
Patent number: 6194421Abstract: Compositions and methods are disclosed for treating a patient infected with a metazoan parasite by inhibiting the enzymatic action of the metazoan parasite protease, wherein there is employed at least one compound of formula I A—X—B wherein A is a substituted or unsubstituted heteroaromatic ring system comprising one to three rings which binds to at least one of the S2, S1 and S1′ subsites; B is a substituted or unsubstituted homoaromatic ring system comprising one to three rings which binds to at least one of the S1′, S1 and S2 subsites; and X is —C═C—C(═O)—. These compositions and methods have particular utility in the treatment of schistosomiasis, malaria and other infectious diseases.Type: GrantFiled: December 30, 1997Date of Patent: February 27, 2001Assignee: The Regents of the University of CaliforniaInventors: Fred E. Cohen, James H. McKerrow, George L. Kenyon, Zhe Li, Xiaowu Chen, Baoqing Gong, Rongshi Li
-
Patent number: 6140368Abstract: The present invention relates to a novel class of compounds that are potent inhibitors of HIV reverse transcriptase and HIV integrase. In addition to being multienzyme inhibitors, the inventive compounds of the present invention are remarkable in at least two other respects. First, they do not appear to be toxic to cells at typical therapeutic concentrations. Second, they appear to be equally effective against mutant strains of HIV reverse transcriptase commonly found in patients who have developed resistance to current reverse transcriptase inhibitors. Because the inventive compounds show promise in combatting viral resistance and are potent inhibitors of both HIV reverse transcriptase and integrase, they are ideal candidates for use in combination with existing therapies or alone in treating AIDS or HIV infection.Type: GrantFiled: May 4, 1998Date of Patent: October 31, 2000Assignees: The Regents of the University of California, Rutgers, The University of New JerseyInventors: George L. Kenyon, Margaret Stauber, Karl Maurer, Dolan Eargle, Angelika Muscate, Andrew Leavitt, Diana C. Roe, Todd J. A. Ewing, Allan G. Skillman, Jr., Edward Arnold, Irwin D. Kuntz, Malin Young
-
Patent number: 5811460Abstract: A water soluble derivative of buckministerfullerene (C.sub.60) having antiviral and virucidal properties is used to inhibit human retroviral replication and infections. The derivatized fullerene is symmetrically substituted with polar organic moieties containing 1 to 20 carbon atoms and optionally further containing oxygen or nitrogen.Type: GrantFiled: January 24, 1994Date of Patent: September 22, 1998Assignee: The Regents of the University of CaliforniaInventors: Simon H. Friedman, Raymond F. Schinazi, Fred Wudl, Craig L. Hill, Diane L. De Camp, Rintje P. Sijbesma, George L. Kenyon
-
Patent number: 5739170Abstract: Compositions and methods are disclosed for treating a patient infected with a metazoan parasite by inhibiting the enzymatic action of the metazoan parasite protease, wherein there is employed at least one compound of formula IA--X--Bwherein A is a substituted or unsubstituted homoaromatic ring system comprising one to three rings which bind to at least one of the S2, S1 and S1' subsites; B is a substituted or unsubstituted homoaromatic ring system comprising one to three rings which bind to at least one of the S1', S1 and S2 subsites; and X is --C.dbd.C--C(.dbd.O)--. These compositions and methods have particular utility in the treatment of schistosomiasis, malaria, and other infectious diseases.Type: GrantFiled: March 30, 1995Date of Patent: April 14, 1998Assignee: The Regents of the University of CaliforniaInventors: Fred E. Cohen, James H. McKerrow, George L. Kenyon, Zhe Li, Xiaowu Chen, Baoqing Gong, Rongshi Li
-
Patent number: 5705333Abstract: The present invention provides novel nucleic acid mimics (termed "PENAMs") comprising a peptidic backbone and nucleotidic sidechains; the sidechains being oriented in such a way that the PENAM is homomorphous to target nucleic acids with which it can effectively hydrogen bond. Homomorphism is achieved by the incorporation of unusual sterochemical centers, including D-chiral centers and quasi-chiral centers, into the peptidic backbone. The PENAMs are useful for targeting nucleic acid sequences in order to modulate their activity in an "antisense" manner. Targeting can also be used to detect, isolate or modify target nucleic acids.Type: GrantFiled: August 5, 1994Date of Patent: January 6, 1998Assignee: The Regents of The University of CaliforniaInventors: Vibhakar J. Shah, George L. Kenyon, Irwin D. Kuntz
-
Patent number: 5610192Abstract: Compositions and methods for treating a patient infected with a metazoan parasite by inhibiting the enzymatic action of the metazoan parasite protease. The compositions comprise at least one metazoan protease inhibitor which binds to the S2 subsite and at least one of the S1 and S1' subsites of the metazoan parasite protease. The methods comprise administration to a patient infected with a metazoan parasite of at least one metazoan protease inhibitor in an amount effective to inhibit the protease of the metazoan parasite, thereby killing the parasite.Type: GrantFiled: March 28, 1995Date of Patent: March 11, 1997Assignee: The Regents of the University of CaliforniaInventors: Fred E. Cohen, James H. McKerrow, Christine S. Ring, Philip J. Rosenthal, George L. Kenyon, Zhe Li